Immatics NV (IMTX)

Currency in USD
9.86
-0.29(-2.86%)
Closed·
10.05+0.19(+1.93%)
·
IMTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.7410.22
52 wk Range
3.3012.41
Key Statistics
Prev. Close
10.15
Open
9.96
Day's Range
9.74-10.22
52 wk Range
3.3-12.41
Volume
223.91K
Average Volume (3m)
403.98K
1-Year Change
111.588%
Book Value / Share
4.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.50
Upside
+97.77%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Immatics NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Immatics NV Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Compare IMTX to Peers and Sector

Metrics to compare
IMTX
Peers
Sector
Relationship
P/E Ratio
−5.8x−1.6x−0.5x
PEG Ratio
0.00−0.020.00
Price/Book
2.4x1.5x2.6x
Price / LTM Sales
23.6x7.9x3.2x
Upside (Analyst Target)
87.6%435.7%51.1%
Fair Value Upside
Unlock21.7%7.3%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 19.50
(+97.77% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Mizuho
Buy25.00+153.55%23.00MaintainFeb 19, 2026
BofA Securities
Buy17.00+72.41%14.00MaintainJan 07, 2026
Leerink Partners
Buy17.00+72.41%16.00MaintainDec 04, 2025
Mizuho
Buy23.00+133.27%19.00MaintainNov 19, 2025
Guggenheim
Buy19.00+92.70%16.00MaintainNov 18, 2025

Earnings

Latest Release
Mar 05, 2026
EPS / Forecast
-0.28 / -0.4116
Revenue / Forecast
19.00M / 9.59M
EPS Revisions
Last 90 days

IMTX Income Statement

People Also Watch

289.02
EVR
-4.54%
89.33
NBIS
-6.61%
502.14
APP
-1.26%
75.79
SSNC
+0.41%
135.19
BE
-15.50%

FAQ

What Is the Immatics NV (IMTX) Stock Price Today?

The Immatics NV stock price today is 9.86 USD.

What Stock Exchange Does Immatics NV Trade On?

Immatics NV is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immatics NV?

The stock symbol for Immatics NV is "IMTX."

What Is the Immatics NV Market Cap?

As of today, Immatics NV market cap is 1.32B USD.

What Is Immatics NV's Earnings Per Share (TTM)?

The Immatics NV EPS (TTM) is -1.61.

When Is the Next Immatics NV Earnings Date?

Immatics NV will release its next earnings report on May 19, 2026.

From a Technical Analysis Perspective, Is IMTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Immatics NV Stock Split?

Immatics NV has split 0 times.

How Many Employees Does Immatics NV Have?

Immatics NV has 645 employees.

What is the current trading status of Immatics NV (IMTX)?

As of Mar 08, 2026, Immatics NV (IMTX) is trading at a price of 9.86 USD, with a previous close of 10.15 USD. The stock has fluctuated within a day range of 9.74 USD to 10.22 USD, while its 52-week range spans from 3.30 USD to 12.41 USD.

What Is Immatics NV (IMTX) Price Target According to Analysts?

The average 12-month price target for Immatics NV is 19.50 USD, with a high estimate of 25 USD and a low estimate of 11 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +97.77% Upside potential.

What Is the IMTX Premarket Price?

IMTX's last pre-market stock price is 10.06 USD. The pre-market share volume is 210.00, and the stock has decreased by -0.09, or -0.89%.

What Is the IMTX After Hours Price?

IMTX's last after hours stock price is 10.05 USD, the stock has decreased by 0.19, or 1.93%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.